BioPlus Co Ltd
KOSDAQ:099430
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioPlus Co Ltd
Note Receivable
BioPlus Co Ltd
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioPlus Co Ltd
KOSDAQ:099430
|
Note Receivable
₩163.8m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
Suheung Co Ltd
KRX:008490
|
Note Receivable
₩4.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
42%
|
CAGR 10-Years
33%
|
|
|
SD Biosensor Inc
KRX:137310
|
Note Receivable
₩2.7B
|
CAGR 3-Years
38%
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
|
|
H
|
HLB Inc
KOSDAQ:028300
|
Note Receivable
₩84.2m
|
CAGR 3-Years
-65%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
T&L Co Ltd
KOSDAQ:340570
|
Note Receivable
₩183.6m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
I
|
Interojo Co Ltd
KOSDAQ:119610
|
Note Receivable
₩2.3B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
19%
|
CAGR 10-Years
18%
|
|
BioPlus Co Ltd
Glance View
BioPlus Co., Ltd. is engaged in the manufacturing and supplying of diverse dermal fillers. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2021-09-27. The firm is engaged in the production and sale of biomaterials for tissue restoration used for temporary improvement of facial wrinkles, namely hyaluronic acid fillers. In addition, the Company is engaged in the production and sale of anti-adhesion agents that reduce the formation of adhesions in surgical areas, biomaterials for joint tissue repair, and other products.
See Also
What is BioPlus Co Ltd's Note Receivable?
Note Receivable
163.8m
KRW
Based on the financial report for Dec 31, 2024, BioPlus Co Ltd's Note Receivable amounts to 163.8m KRW.
What is BioPlus Co Ltd's Note Receivable growth rate?
Note Receivable CAGR 5Y
40%
Over the last year, the Note Receivable growth was -88%. The average annual Note Receivable growth rates for BioPlus Co Ltd have been -50% over the past three years , 40% over the past five years .
